ArticleFrontiers in nutrition2025
Association between RDW-to-albumin ratio and mortality in HFpEF: a retrospective study based on MIMIC-IV and external validation.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Heart failure with preserved ejection fraction (HFpEF) in the intensive care unit (ICU) has high mortality, yet reliable bedside prognostic markers remain limited. The red cell distribution width-to-albumin ratio (RDW/Alb), reflecting inflammation and nutrition, has not been validated in this setting. Methods: This retrospective cohort study queried the MIMIC-IV (v2.2) database for adults (≥18 years) with first ICU admission and HFpEF (left ventricular ejection fraction ≥50% by ICD coding or echocardiographic narrative). RDW and serum albumin within 24 h of ICU entry were used to calculate RDW/Alb, analyzed as tertiles (T1 ≤ 4.08; T2 4.08-5.13; T3 > 5.14). The primary endpoint was all-cause mortality at 30, 90, and 365 days. Kaplan-Meier curves, multivariable Cox regression, restricted cubic splines (RCS), and subgroup analyses were conducted. Prognostic discrimination of RDW/Alb was compared with the triglyceride-glucose (TyG) index in a biomarker-complete subset. Findings were externally validated in 429 HFpEF patients from general wards at our hospital. Results: Among 3,436 ICU-HFpEF patients, 659 (19.2%), 907 (26.4%), and 2,997 (87.3%) deaths occurred at 30, 90, and 365 days, respectively. Mortality rose stepwise across tertiles (30-day: 8.0% vs 16.2% vs 33.3%; log-rank < 0.001). In fully adjusted models, each unit increase in RDW/Alb was associated with 12% higher hazard for 30-day (HR 1.12, 95% CI 1.10-1.15) and 90-day mortality (HR 1.12), and a 10% increase for 1-year mortality (HR 1.10, 95% CI 1.07-1.12). Compared with T1, T3 patients had HRs of 3.13, 3.02, and 1.37 for 30-, 90-, and 365-day mortality (all Conclusion: RDW/Alb is a simple, widely available marker that strongly predicts mortality in ICU patients with HFpEF, outperforming TyG and supporting its role in early risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.